Unraveling the Complexity of Cancer-Related Cognitive Impairment in Breast Cancer—Effect of Differing Treatments and Menopausal Status
Menée à partir de données d'un essai international de phase III portant sur 568 patientes atteintes d'un cancer du sein HR+ ERBB2- (139 patientes avant la ménopause, âge médian : 47,8 ans ; 429 patientes ménopausées, âge médian : 62,3 ans), cette étude analyse leurs déficiences cognitives en lien avec un traitement endocrinien avec ou sans chimiothérapie, en fonction du statut ménopausique
Cancer-related cognitive impairment (CRCI) is an important clinical problem that affects many patients with cancer and includes difficulties in memory, attention, processing speed, and executive function. Studies including patient-reported outcomes (PROs) suggest that 50% to 75% of patients receiving chemotherapy experience CRCI. These problems negatively affect daily functioning and can persist for many years. Given that CRCI exists in the short and long term, better understanding of the effect of disease and various treatment combinations on CRCI and whether there are differential effects in the magnitude of CRCI by treatment regimen and the contributions of host factors is needed.
JAMA Oncology , éditorial, 2025